4.1 Review

The Hyperfiltering Kidney in Diabetes

期刊

NEPHRON
卷 136, 期 4, 页码 277-280

出版社

KARGER
DOI: 10.1159/000448183

关键词

Hyperfiltration; Diabetes; Intraglomerular pressure; Diabetic nephropathy

资金

  1. Astra-Zeneca
  2. Boehringer Ingelheim
  3. Eli Lilly
  4. Novo Nordisk
  5. Janssen
  6. Merck

向作者/读者索取更多资源

Hyperfiltering kidney is a typical feature of diabetes. Improvement observed with regard to glucose control and blood pressure control reduces the high glomerular filtration rate and may contribute to retard the appearance and the progression of diabetic renal disease. Although the mechanism of hyperfiltration is still unclear, there is mounting evidence that the increased reabsorption of glucose and sodium by sodium glucose transporter-2 (SGLT-2) is involved in this altered renal function. There is a possibility that SGLT-2 inhibition may correct hyperfiltration in diabetes, adding a new therapeutic approach to halt renal disease in patients with diabetes. (C) 2016 S. Karger AG, Basel

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据